Napp Pharmaceuticals says the UK is the first country in Europe to launch flutiform k-haler, a breath-actuate inhaler for adolescents and adults living with asthma.
flutiform has been available in Europe for the treatment of asthma in adults and adolescents (≥12 years old) since 2012 and has a tolerability profile supported by extensive clinical evidence and real-world use for six years across Europe and Asia-Pacific